Rationale: Atherosclerosis is characterized by lipid accumulation in the vessel wall, inflammation, and both macrophage and vascular smooth muscle cell (VSMC) apoptosis. However, whereas VSMC apoptosis in mice with established atherosclerotic plaques or hyperlipidemia increases serum levels of the proatherogenic cytokines monocyte chemotactic protein (MCP)-1, tumor necrosis factor ␣, and interleukin (IL)-6, the link between hyperlipidemia, apoptosis and inflammation, and the mechanisms by which apoptotic cells promote inflammation in atherosclerosis are unknown. Objective: To determine whether hyperlipidemia affects apoptotic cell clearance, and identify the molecular pathways downstream of VSMC apoptosis that may promote inflammation. Methods and Results: We find that human VSMCs are potent and efficient phagocytes of apoptotic human VSMCs, but phagocytosis is significantly reduced by oxidized low-density lipoprotein in vitro or hyperlipidemia in vivo. Necrotic human aortic VSMCs release IL-1␣, which induces IL-6 and MCP-1 production from viable human VSMCs in vitro. In contrast, secondary necrotic VSMCs release both IL-1␣ and caspase-activated IL-1␤, augmenting IL-6 and MCP-1 production. Conditionally inducing VSMC apoptosis in situ in hyperlipidemic SM22␣-hDTR/ApoE ؊/؊ mice to levels seen in human plaques increases serum MCP-1, tumor necrosis factor ␣, and IL-6, which is prevented by blocking IL-1. Conclusions: We conclude that VSMC necrosis releases IL-1␣, whereas secondary necrosis of apoptotic VSMCs releases both IL-1␣ and ␤. IL-1 from necrotic VSMCs induces the surrounding viable VSMCs to produce proinflammatory cytokines. Thus, failed clearance of apoptotic VSMCs caused by hyperlipidemia in vivo may promote the increased serum cytokines and chronic inflammation associated with atherosclerosis. (Circ Res.
T he phagocytosis of senescent or dead cells plays a pivotal role in development, normal tissue turnover, regulation of the immune system, and the resolution of inflammation. Phagocytosis of apoptotic cells generally leads to reduced expression of inflammatory cytokines such as tumor necrosis factor (TNF)-␣ and interleukin (IL)-12 1, 2 and increased production of antiinflammatory cytokines such as IL-10 1 and transforming growth factor ␤. 2 However, if dying or apoptotic cells are not swiftly phagocytosed they may undergo necrosis, with lysis releasing endogenous "danger signals" 3 able to induce inflammation. Indeed, a growing body of evidence suggests that defective phagocytosis may be involved, or even causative, in many inflammatory diseases including rheumatoid arthritis, 4 lung injury, autoimmune diseases, 5 and, more recently, atherosclerosis. 6, 7 Atherosclerosis is a chronic inflammatory disease in which both innate and adaptive immunity modulate disease progres-sion. 8 Many advanced atherosclerotic plaques consist of a fibrous cap of vascular smooth muscle cells (VSMCs), collagen, and extracellular matrix, with macrophages and T lymphocytes present in superficial regions of the plaque. Myocardial infarction occurs when the fibrous cap ruptures to expose the lipid-rich core, with subsequent thrombosis occluding the vessel. Plaque stability is determined by its mechanical properties, in particular the number of VSMCs and their ability to synthesize extracellular matrix. 9 Both apoptosis and necrosis occur in advanced plaques at higher levels than those seen in normal vessels, 10 -13 and levels are increased in patients with unstable versus stable angina 14 along with serum levels of inflammatory factors such as IL-6 15 and C-reactive protein. 16 It has been suggested that reduced phagocytosis within atherosclerotic plaques may promote both chronic inflammation 6, 7 and plaque progression. 17, 18 However, the identity of phagocytes in atherosclerosis, the mechanisms linking failed phagocytosis and inflammation, and the cytokines promoting inflammation are all unknown. The phagocyte surface expresses a number of scavenger receptors responsible for uptake of apoptotic cells that are also involved in atherosclerosis. 5 For example, scavenger receptor-A, CD36, and LOX-1 (lectin-like oxidized low-density lipoprotein receptor) mediate uptake of modified lipoproteins by macrophages and foam cells 19 and thus oxidized low-density lipoprotein (oxLDL) can delay engulfment by competing for scavenger receptors. 6, 20 Furthermore, a hallmark of conditions that lead to an accumulation of apoptotic cells is loss of immune tolerance, whereby apoptotic antigens may be cross-presented by dendritic cells, which can lead to autoimmunity. 21 Many autoantibodies develop as atherosclerosis progresses, including anti-oxLDL, anti-nuclear, anti-heat shock proteins, and anti-cardiolipin. 22, 23 We have recently described SM22␣-hDTR/ApoE Ϫ/Ϫ mice, in which transgenic expression of the human diphtheria toxin receptor (hDTR) from the minimal SM22␣ promoter enables conditional induction of VSMC-specific apoptosis. 24 VSMC apoptosis in normal arteries is silent, with no inflammation or pathology. In contrast, VSMC apoptosis in hyperlipidemic SM22␣-hDTR/ApoE Ϫ/Ϫ mice resulted in both local and systemic inflammation 24 and pathological changes in vessel morphology. 25 Although these findings suggest that phagocytosis may be reduced enough during hyperlipidemia to allow necrosis, with leakage of intracellular contents able to induce inflammation, this has not previously been proven. Therefore, we have used SM22␣-hDTR/ApoE Ϫ/Ϫ mice to determine the mechanisms underlying apoptosis-induced inflammation during atherosclerosis. We show that VSMCs are efficient phagocytes of apoptotic VSMCs in vitro and in vivo. Hyperlipidemia alone is sufficient to reduce phagocytosis in the vessel wall, resulting in necrosis of apoptotic VSMCs and leakage of intracellular IL-1␣. IL-1␣ subsequently acts on the surrounding viable VSMCs inducing them to release IL-6 and monocyte chemotactic protein (MCP)-1, thus perpetuating a chronic inflammatory state.
Methods
All materials were purchased from Sigma-Aldrich unless otherwise stated.
Animal Protocols
Animal experiments were performed under United Kingdom Home Office licensing. Recombinant DT (Quadratech Diagnostics) was prepared in 0.9% saline/0.2% BSA and stored at Ϫ80°C until use. To assess phagocytosis in vivo, mice were either left on normal chow (SDS), or placed on high fat diet (21% fat, 0% cholate, 0.2% cholesterol [SDS]) for 2 weeks, followed by 3 doses of DT (5 ng/g) intraperitoneally, each a day apart. Mice were euthanized under CO 2 , blood was collected, and vessels were removed and fixed on days Ϫ1, 1, 3, and 6 after DT treatment. IL-1 receptor antagonist (IL-1RA) or carrier control (Amgen) was administered intraperitoneally (25 mg/kg per day) from the first DT injection until euthanasia. Serum cytokine levels were quantified using the mouse inflammation array (Becton Dickinson), and lipids were determined using a Dade-Behring Dimension analyzer.
Histology and Immunohistochemistry
Tissue was processed as previously described. 24 Primary antibodies used were Mac 3 (Pharmingen) and cleaved caspase-3 (CC3) (Cell Signaling). All sections were stained with biotinylated secondary antibodies and detected with ABC reagents (Vector Laboratories). TUNEL was performed as previously described. 24 Images were captured as previously described. 24 Total number of apoptotic VSMCs were counted per whole aortic section and expressed per millimeter squared. Counts within mice were made on a minimum of 3 independent planes at least 50 m apart.
Cell Culture
Human VSMCs were isolated from aortas of cardiac transplant patients with informed consent and local ethics approval. Cells were cultured in DMEM supplemented with 10U/mL penicillin, 10 mg/mL streptomycin, 5 mg/mL L-glutamine, and 10% FCS. Subconfluent VSMCs were trypsinized and resuspended in serum-free DMEM at 7ϫ10 5 cells/mL. Cell membranes were disrupted by 2 rounds of freeze/thaw in liquid nitrogen, then stored at Ϫ20°C or used as indicated. Apoptotic VSMCs were prepared by incubating with the Fas antibody CH.11 (100 ng/mL; Upstate) and cycloheximide (20 g/mL) for 10 hours and made necrotic as above. Necrotic lysates were also prepared by incubating VSMCs with digitonin at RT for 10 minutes.
In Vitro Phagocytosis Assay
VSMCs were either labeled with cell tracker orange and cultured overnight, or with cell tracker green (Molecular Probes) and apoptosis induced. Green apoptotic bodies were incubated with orange VSMCs for 2 hours, uneaten bodies were washed off, cells were trypsinized and analyzed by flow cytometry. Where indicated, phagocyte VSMCs were pretreated with fucoidan (100 g/mL), poly-I (100 g/mL), glucosamine (20 mmol/L), galactosamine (20 mmol/L), or oxLDL (100 g/mL; Biogenesis) for 15 minutes at 37°C.
Cytokine Release Assay
VSMCs were plated at 15ϫ10 3 cells per well of a 24-well plate, allowed to adhere, and incubated in serum-free DMEM for 24 hour. Fresh serum-free DMEM was added to a final volume of 500 L including treatments, incubated for 6 hours and then assayed by ELISA (PeproTech) for cytokine level. Where indicated necrotic lysates were treated with protease K (0.2 mg/mL), DNase (20 U/mL), or lipase (3000 U/mL) at 37°C for 30 minutes. Where indicated, VSMCs were preincubated with Box A (10 g/mL) or IL-1RA (100 ng/mL), and necrotic lysates were preincubated with Hirudin (10U/mL) or neutralizing antibodies (2 g/mL) for 15 minutes. Immunodepletion was achieved by crosslinking IL-1␣ to protein G, followed by 2 rounds of depletion at 4°C for 1 hour. "Sham IL-1␣ deplete" controlled for carryover of neutralizing antibody. 
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Glycerol Gradients
Two continuous 5% to 25% glycerol gradients were poured in parallel, overlayed with either necrotic VSMC lysate or native molecular weight markers (Amersham) and ultracentrifuged at 280 000 g for 27 hours at 4°C. Fractions were collected from bottom to top from both separations. Necrotic VSMC fractions were assayed for cytokine-inducing activity, whereas marker fractions were sub-jected to SDS-PAGE and silver staining to allow estimation of peak molecular weight content within each fraction.
Western Blotting
Western blotting was performed according to standard laboratory techniques. Control and apoptotic samples were whole cell lysates of control and apoptotic VSMCs, whereas necrotic and secondary necrotic samples were control and apoptotic VSMCs that had been freeze/ thawed before lysis, respectively. Samples were loaded on the basis of equal numbers of extracted cells.
Statistics
Nonparametric tests were used for immunohistochemical and morphological analysis, as normality of data distribution could not be guaranteed. Comparison between 3 or more unpaired groups was made with the Kruskal-Wallis test, whereas comparisons between 2 unpaired groups were made with the Mann-Whitney U test (SPSS). Continuous data were analyzed by ANOVA (Excel).
Results
VSMC Phagocytosis of Apoptotic VSMCs Is Inhibited by Hyperlipidemia
We have previously shown that primary rat VSMCs can phagocytose apoptotic VSMCs in vitro 26 ; however, these findings were entirely descriptive, any consequences of phagocytosis (such as inflammation) or their mechanism were not examined, and we did not study how perturbation of phagocytosis might alter vessel structure or regulate inflammation in vivo. Using a quantitative FACS-based phagocytosis assay we confirmed that
VSMCs are efficient phagocytes of apoptotic VSMCs, via a mechanism that was attenuated with the pan-scavenger receptor inhibitors poly-I and fucoidan ( Figure 1 ). Importantly, phagocytosis was also significantly reduced by oxLDL ( Figure 1 ). We have previously demonstrated that apoptotic VSMCs are cleared from the vessel wall of mice without the presence of mononuclear phagocytes, 24, 25 suggesting that VSMCs also readily phagocytose apoptotic VSMCs in vivo. We therefore examined whether hyperlipidemia alone could reduce phagocytosis within the vessel wall before plaque development and before the appearance of monocyte/macrophages. The SM22␣-hDTR/ApoE Ϫ/Ϫ mice allow conditional and dose-dependent induction of VSMC apoptosis. By inducing VSMC apoptosis with a "bolus" of DT and subsequently counting apoptotic cells over time, we can calculate a rate of clearance for VSMCs in vivo. This unique in vivo model measures phagocytosis kinetics, rather than apoptotic frequency at a single time point, as is more usual. This removes the uncertainty as to whether manipulations also alter the rate of apoptosis, and avoids trying to determine histologically whether apoptotic bodies are free, bound, or ingested. Two weeks of fat-feeding resulted in a significant 2.3- (Figure 2A and 2B) . The rate of VSMC phagocytosis in fat-fed mice was markedly slower than chow-fed mice, such that almost double the number of apoptotic cells remained in fat-fed mice at day 6, despite an equivalent initial level of apoptotic VSMCs at day ϩ1 ( Figure 2C ). To further confirm that fat feeding did not alter induction of apoptosis, we also examined the level of CC3-positive cells (Online Figure II) . DT administration (Day -1) induced significant numbers of CC3-and TUNEL-positive cells; there was no significant difference in CC3 or TUNEL staining found between chow and fat-fed mice at this time point ( Figure 2C ), suggesting no effect of diet on induction of apoptosis. After cessation of DT the level of CC3 positive cells rapidly fell, with no positive cells detectable at days 3 and 6, despite the presence of TUNEL-positive cells. Given that CC3 only marks cells actively undergoing apoptosis, whereas TUNEL labels apoptotic cells until they are phagocytosed, this confirms that the differences in TUNEL-positive cells between chow and fat-fed mice at days 3 and 6 are governed by phagocytosis and not apoptosis induction.
Direct Release of IL-1␣ From Necrotic VSMCs Induces IL-6 and MCP-1 Production From VSMCs
We have previously found that VSMC apoptosis in hyperlipidemic SM22␣-hDTR/ApoE Ϫ/Ϫ mice increases serum levels of the proinflammatory cytokines IL-6, MCP-1, TNF-␣, and IL-12. 24, 25 Given the decrease in phagocytosis observed during hyperlipidemia ( Figure 2C ) we examined whether secondary necrosis of VSMCs (for example, attributable to failed phagocytosis) could release a factor that increases serum cytokines. Necrotic lysate supernatants made by freeze/thawing human aortic VSMCs induced release of IL-6 and MCP-1 from monolayers of human VSMCs ( Figure 3A) , via de novo production (Online Figure III) . Necrotic VSMC lysates made by gentle permeabilization with the detergent digitonin gave equivalent results (Online Figure IV) , although necrotic lysates themselves contained negligible IL-6 and MCP-1 (data not shown). The factor(s) responsible was proteinaceous, heat-inactivated, but remained stable at 22°C over 24 hour ( Figure  3B ). The previously described candidates HMGB-1 27 and thrombin 28 were eliminated following a lack of inhibition with their antagonists Box A and hirudin, respectively (Online Figure V) .
Previous studies have identified more than 15 proteins able to mediate release of IL-6 and MCP-1 from VSMCs. We therefore first used glycerol density gradient centrifu- gation to determine the molecular weight of the factor(s), which revealed a single peak of activity for both cytokines within the same fraction of Ϸ17 kDa ( Figure 3C ). We examined the previous candidates identified for a 17-kDa protein exported via nonclassical pathways that may be released by cell necrosis. Both IL-1␣ and IL-1␤ are potent proinflammatory cytokines synthesized by VSMCs that do not possess signal peptides, and are released by nonclassical export (reviewed elsewhere 29 ). Indeed, IL-1RA, which blocks all ligands binding to the IL-1 receptor 1, completely abolished all response to necrotic VSMC lysates ( Figure 4A ). Individual neutralizing antibodies for IL-1␣ and ␤ subsequently identified IL-1␣ to be the single protein from necrotic VSMCs able to mediate IL-6 and MCP-1 release from VSMCs ( Figure 4B ). Multiplex cytokine analysis of supernatants collected from viable VSMCs incubated with necrotic VSMCs confirmed that only IL-6 and MCP-1 are released, with no significant production of IL-1␤, IL-2, IL-10, IL-12, IL-18, interferon-␥, or TNF-␣ (Online Figure VI) .
The finding that IL-1␣ can mediate inflammation in response to necrotic cells has recently been reported by others, 30 -32 however controversy exists as to whether IL-1␣ acts as a secondary signal released by macrophages in response to unknown necrotic factors, 30 or whether IL-1␣ is directly released on cell lysis. 31, 32 By immunodepleting IL-1␣ from necrotic lysates ( Figure 4C ), we found a complete loss of IL-6 and MCP-1-inducing activity ( Figure 4D) , confirming that IL-1␣ alone is indeed a direct molecular danger signal released from necrotic VSMCs.
Secondary Necrotic VSMCs Are More Inflammatory Because of the Combined Effect of IL-1␣ and IL-1␤
Although we have shown that primary necrosis releases IL-1␣, our original hypothesis requires IL-1␣ to be functional when released on necrotic lysis after apoptosis. We therefore examined the efficacy of necrotic lysates made from equal numbers of both viable and apoptotic (secondary necrotic) VSMCs to induce VSMC cytokine release. Surprisingly, secondary necrotic VSMC lysates were more effective at activating live VSMCs to produce cytokines ( Figure 5A ). Examination of necrotic lysates by Western blotting revealed equal amounts of IL-1␣ present within control and apoptotic lysates, and equal amounts of calpain-cleaved IL-1␣ within necrotic and secondary necrotic lysates ( Figure 5B ). How- ever, activated IL-1␤ was increased in apoptotic and secondary necrotic VSMC lysates ( Figure 5C ), suggesting the increased activity of secondary necrotic lysates is attributable to the combined action of IL-1␣ and caspase-activated IL-1␤.
The Increase in Serum Proinflammatory Cytokines After VSMC Apoptosis In Vivo Depends on IL-1
We have previously reported that acute induction of VSMC apoptosis in mice with established plaques 24 or chronic VSMC apoptosis during atherogenesis 25 increases serum inflammatory cytokines. However, in both cases the vessel wall contained substantial numbers of inflammatory cells, which could have been a potential source of cytokines. We therefore examined the serum cytokine response to VSMC apoptosis in SM22␣-hDTR/ApoE Ϫ/Ϫ mice after only 2 weeks of fat-feeding, when plaques are not present. Acute medial VSMC apoptosis in fat-fed mice induced significant increases in the serum level of IL-6, MCP-1 and TNF-␣, which rapidly returned to baseline ( Figure 6A ) with a time course which paralleled the removal of most of the remaining apoptotic cells ( Figure 2C ). However, normal chow-fed SM22␣-hDTR/ ApoE Ϫ/Ϫ mice showed no increase in serum cytokines ( Figure 6A ), despite the same initial level of apoptotic VSMCs ( Figure 2C) . Importantly, fat feeding alone, without induction of VSMC apoptosis, resulted in no increase in serum cytokines compared to control chow-fed animals (Online Figure VII) . We have previously found that VSMC apoptosis also increases local expression of MCP-1 within established plaques. However, despite an increase in serum MCP-1 ( Figure 6A ), no inflammatory cells were detected within the vessel wall ( Figure 2B ). To determine whether IL-1 was responsible for inducing serum inflammatory cytokines, we administered recombinant IL-1RA or carrier control concurrent with DT treatment throughout the experimental time course. IL-1RA administration resulted in a statistically significant decrease in IL-6, and a borderline reduction in TNF-␣ ( Figure 6B ). IL-1RA did not reduce the number of apoptotic bodies (67.0Ϯ7.6 versus 65.6Ϯ5.6 cells/mm 2 , IL-1RA versus carrier, Pϭ0.89) present at death or reduce serum lipids (data not shown), indicating that its effect on IL-6 and TNF-␣ levels were attributable to neutralization of IL-1, most likely released from necrotic VSMCs.
Discussion
Atherosclerosis is a disease characterized by lipid accumulation in the vessel wall, cell death and inflammation. Apoptosis in VSMCs and macrophages may both promote inflammation and alter plaque composition. 17, 18, 24, 25, 33 However, the mechanisms by which apoptotic cells promote inflammation in atherosclerosis are unclear. One possibility is that failure to clear apoptotic vascular cells results in secondary necrosis, with either subsequent release of inflammatory cytokines or signaling to local healthy cells to stimulate cytokine release. Although much research has endeavored to assess the impact of failed phagocytosis in vivo, many manipulations intended to alter phagocytosis (eg, knock out of phagocytic receptors) are marred by redundancy in the clearance system and result in little pathology. 34 In contrast, we report that conditional induction of VSMC apoptosis during hyperlipidemia results in accumulation of apoptotic bodies, followed by a robust IL-1-dependent increase in serum inflammatory cytokines, which rapidly resolves after removal of the stimulus (summarized in Online Figure VIII ). To our knowledge, this is the first direct demonstration of the inflammatory consequences of failed VSMC phagocytosis in situ, in vivo.
Although it has been suggested that failed phagocytosis within atherosclerotic plaques may be responsible for the inflammation associated with the disease, 6,7 the complex microenvironment makes it difficult to quantify kinetics of phagocytosis, the cells involved, and the number of uncleared apoptotic cells that would elicit an inflammatory response. We have previously shown that systemic inflammation results from apoptosis in Ϸ15% of VSMCs within established plaques, 24 or in Ϸ1% of VSMCs in normal vessels after fat-feeding. 25 In the present study, we demonstrate that in hyperlipidemic mice, induction of apoptosis in Ϸ1% of VSMCs (Ϸ66 cells/mm 2 ) is sufficient to induce high levels of circulating IL-6, TNF-␣, and MCP-1, which return to baseline by day 6 when Ͻ0.5% of apoptotic VSMCs (Ϸ27 cells/mm 2 ) remain. These changes in inflammatory cytokines were not seen in normolipidemic mice despite similar initial levels of apoptosis, supporting the concept that inflammation requires both VSMC apoptosis and hyperlipidemia acting in concert, most likely via reduced phagocytosis resulting in secondary necrosis. Apoptotic frequencies of 1% are commonly found in advanced plaques in humans and mice, 13 suggesting that uncleared apoptotic cells may be potent stimuli sustaining the inflammation associated with atherosclerosis.
Our study supports recent observations that inhibition of local phagocytosis in the vessel wall can promote adverse consequences on plaque structure and inflammation. For example, knock out or mutation of the Mertk receptor or lactadherin resulted in an accumulation of apoptotic cells, increased size of necrotic cores, but lesion size was either unchanged 35 or near doubled. 17, 18 In contrast, increased macrophage apoptosis by directed deletion of Bcl-X L 36 or total phospholipase C␤3 loss, 37 without manipulation of phagocytosis, led to either no change in plaque and necrotic area 36 or a large reduction in both necrotic core and plaque size. 37 These discrepancies suggest that accumulation of apoptotic cells per se within a plaque does not drive a similar phenotype, highlighting the need to understand the specific downstream interactions between the apoptotic/necrotic cell type, the "responding" cell, and the local milieu at different stages of plaque development.
This discovery that VSMCs are normally highly efficient phagocytes, clearing apoptotic VSMCs in vivo without the need for macrophages, and that short periods of fat-feeding inhibit VSMC phagocytosis is most surprising. Previous work has only examined presence of apoptotic bodies within established atherosclerosis, 7 in part, because of the rarity of apoptosis before plaque development. 13 Many mechanisms have been proposed to explain failed clearance within the plaque microenvironment, including competitive inhibition of phagocytic receptors, 20 oxidative stress, 7 and anti-oxLDL autoantibody binding to apoptotic cells. 38, 39 However, most of these situations require macrophages, or longer time frames, and therefore should not affect clearance in the present study. Importantly, hyperlipidemia may also in- hibit phagocytosis in other organs. For example, uncleared apoptotic cells within the lymph nodes of Fas ligand mutant gld/ApoE Ϫ/Ϫ mice were significantly increased on fat-feeding, also suggesting an effect of hyperlipidemia remote from the plaque microenvironment. 40 IL-1␣ and IL-1␤ represent the prototypic cytokines and bind to the same receptor to induce identical biological functions. Both IL-1␣ and -␤ can be synthesized by endothelial cells, VSMCs, and macrophages and can induce cytokine production, activation of endothelial cells and macrophages, increased adhesion molecules, proliferation of VSMCs and increased vascular permeability, 41 all processes important during atherogenesis. Indeed, atherosclerosis is reduced in IL-1␤ knockout mice, 42, 43 whereas IL-1RA-deficient mice develop more neointima after balloon injury. 44 In contrast to IL-1␤, the role of IL-1␣ has been less clear. 45 Our findings suggest that following primary necrosis only IL-1␣ acts as an endogenous danger signal, whereas after secondary necrosis, both IL-1␣ and apoptosis-activated IL-1␤ act in combination. This additive effect following secondary necrosis underscores the adverse consequences of failed apoptotic cell clearance, effectively resulting in a greater proinflammatory potential for a given number of cells than during primary necrosis.
In summary, we have shown that following VSMC apoptosis reduced phagocytosis caused by hyperlipidemia may result in secondary necrosis with release of IL-1␣ and IL-1␤. These cytokines act within the vessel wall on the surrounding viable VSMCs, inducing them to produce proinflammatory cytokines, including IL-6 and MCP-1. Thus, "amplification" of an IL-1-mediated signal from a small quantity of necrotic cells ultimately results in both a local and systemic increase in inflammatory cytokines (Online Figure VIII) . Once the remaining apoptotic and necrotic debris has been cleared, the stimulus is removed and serum cytokines return to baseline. We believe the combination of VSMC death and hyperlipidemia may promote an as yet unreported role for IL-1dependant inflammation during atherosclerosis.
